Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer. - Wikidata - wikimedia - TriplyDB

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.

http://www.wikidata.org/entity/Q35076221

about

Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?AXL kinase as a novel target for cancer therapy Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma.Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs.Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report.Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer.Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.AXL receptor tyrosine kinase as a therapeutic target in NSCLC.Recent advances in targeted advanced lung cancer therapy in the elderly.EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer.ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors.Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients.Function of Axl receptor tyrosine kinase in non-small cell lung cancer.Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis.Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET).Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis.Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA.Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China Frequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital

P2860

Q26778318-8BD87538-0989-43CD-85EC-319981E437F4 Q26863442-F625EA6E-F2D3-49F7-9EAE-5D5791366B0A Q27853391-B26D9B8B-711B-48A1-870B-F14A05C171F7 Q28083239-6452D82E-F6E7-4E57-88E1-72853CF7324D Q33621143-53DEC1C1-A6E0-4C48-B6C7-0DF48A1C3412 Q34293223-B12562A2-8FA8-4BE2-85B7-B29E319683BE Q35602598-EFA955EB-6A07-44F5-A4CB-A865BED4D210 Q36021012-83CB2C32-F576-4CFB-8175-510AA67D4F40 Q36184824-B20CA59A-8F70-4D8B-BB6C-8B769B21D116 Q37085219-6550113F-713B-4E88-BCB5-88A7B6EED63D Q37588281-B160F9CF-BF89-4BB0-BAB6-B2D87DAF0B52 Q38258948-80449382-FA6C-4DB2-892C-86DA14808036 Q38797202-561D71CC-6861-4F6E-8C07-8CB7EB6F9634 Q39139917-FD636F0C-9EA3-49AD-9CFE-3D6E7C1E2B36 Q40143039-7EE4AF6B-3088-4EBB-B460-79EEEEB9D77C Q40562646-1877353D-4A3E-40BC-A6B4-44FF54A8F4AB Q41940444-450C0A08-6809-4C7C-8484-96A994D3AE69 Q42378535-077C4C0D-0236-402B-A3EB-935BFFC17DF3 Q44249512-B98D00D7-CDCF-4B80-AB91-3A535D39AB83 Q47116265-3CF1EE85-A4D3-4CDA-A4C5-3E235B98E2E7 Q47159292-E49BDBDB-6360-4A08-9F43-D8A5C65B9DF7 Q49636410-2B0B0EA6-1632-4A34-A7B3-1113F0C9233C Q49995592-7835B7AF-7AA3-498A-86AA-E90400CB003D Q53878549-D2D34A23-C329-49B0-AADD-C1F573C44F1A Q54340079-5D0C66DE-40DA-413C-B84D-7E110D2A98C8 Q54977581-E57FCD90-DD7E-45C2-BB1F-440F286123E9 Q55226999-AE1BD2AD-7CF0-42BC-BCCD-5298C678F2F5 Q58603542-2583F771-2A09-4E49-A786-CB6897F5BF38 Q58776687-7504E3FB-3AEB-4D8A-9190-1299FE11D573

P2860

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.

http://www.wikidata.org/entity/Q35076221

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Mechanisms of acquired resista ...... ean patients with lung cancer.

@ast

Mechanisms of acquired resista ...... ean patients with lung cancer.

@en

type

label

Mechanisms of acquired resista ...... ean patients with lung cancer.

@ast

Mechanisms of acquired resista ...... ean patients with lung cancer.

@en

prefLabel

Mechanisms of acquired resista ...... ean patients with lung cancer.

@ast

Mechanisms of acquired resista ...... ean patients with lung cancer.

@en

P1433

Q35076221-60A92D90-1D70-4FDD-8216-3AB85B0EDD7D

P1476

Q35076221-FD2ACA41-027B-47C5-97B7-49EE0A4AFE4C

P2093

Q35076221-0BE335EC-AA14-497A-8731-09376D8A13FC

Q35076221-14AC15E0-31D4-4715-B96C-0EB927950A87

Q35076221-4A60BE8F-920D-4DC1-9E2B-EF43C4AB29E2

Q35076221-8EC92E79-942B-4847-ACE5-873539F43A08

Q35076221-9F8F36A7-D6EE-4F5E-8581-A285B9E708E5

Q35076221-C8341819-65DA-4DE7-86C6-71AE6F8A8019

Q35076221-CA279826-9D4B-4465-BD0E-3B75E0E3D172

Q35076221-D49ADD1D-2BE9-4A4A-8D32-48F69780BE69

Q35076221-EACE08DC-A551-466B-9FFB-869EC8496F03

P2860

Q35076221-1760F376-D8C6-44C3-8786-3C3939C552E8

Q35076221-1A9ECB63-5422-4AAF-9FF5-DC21BC016B67

Q35076221-2FB50F43-5046-43C7-B9D2-4137AC7005B0

Q35076221-3BD9C8D5-D7FE-4EF3-9265-13A345D9EBA7

Q35076221-3FA65A87-7C2A-419A-A7D8-307D80597380

Q35076221-40A86685-5812-4DF3-91C7-416D91E2DC6B

Q35076221-5128AC53-8E84-4F34-8B74-BD6EBA0B5BC5

Q35076221-5BFADBC3-0322-4FFF-A392-142F9544D604

Q35076221-6270C115-E2BE-4BCB-BDFD-9290296BA71F

Q35076221-63B1D28E-8BC2-437F-867F-A1E6D68D07AF

P2888

Q35076221-DB8D8A05-1337-4577-B01F-CFE49EA547B5

P304

Q35076221-7A9303C7-8200-4710-B842-88F112B5FF69

P31

Q35076221-E7B40E42-DB70-40CF-9595-7F631B93C488

P356

Q35076221-44E10B35-48CD-4BCE-84BD-CDA14FFFA958

P407

Q35076221-AFBEF1E8-A2AB-486B-AB50-9E699338BA61

P478

Q35076221-BD68B75C-9C53-4A5B-8DAC-D06C62B5C054

P50

Q35076221-03B95AD6-36AD-49B8-B18A-1419BF18877D

Q35076221-8EAC7EAE-3423-49CF-A89F-C4595BC8B4AC

P577

Q35076221-9DF26459-780A-4C78-9CA5-1C4279D08997

P5875

Q35076221-664F528D-224A-4976-A6EF-D718D23A65F8

P6179

Q35076221-6994836E-CDD4-4037-9B9F-EE9DBCF1DDC3

P698

Q35076221-8F0F499E-CFF8-46A0-B7D0-080406FF27EA

P932

Q35076221-CDD2ECEC-41F0-4853-84A6-1B9EFADC8670

P356

1471-2407-13-606

P1433

P1476

Mechanisms of acquired resista ...... rean patients with lung cancer

@en

P2093

Chang-Min Choi

http://www.w3.org/2001/XMLSchema#string

Dae Ho Lee

http://www.w3.org/2001/XMLSchema#string

Jae Cheol Lee

http://www.w3.org/2001/XMLSchema#string

Jin Kyung Rho

http://www.w3.org/2001/XMLSchema#string

Jung-Shin Lee

http://www.w3.org/2001/XMLSchema#string

Sang-We Kim

http://www.w3.org/2001/XMLSchema#string

Se Jin Jang

http://www.w3.org/2001/XMLSchema#string

Woo Sung Kim

http://www.w3.org/2001/XMLSchema#string

Young Soo Park

http://www.w3.org/2001/XMLSchema#string

P2860

Profiling critical cancer gene mutations in clinical tumor samples

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells

P2888

1471-2407-13-606

P304

606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-13-606

http://www.w3.org/2001/XMLSchema#string

P407

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259472816

http://www.w3.org/2001/XMLSchema#string

P6179

1049567221

http://www.w3.org/2001/XMLSchema#string

P698

24369725

http://www.w3.org/2001/XMLSchema#string

P932

3877961

http://www.w3.org/2001/XMLSchema#string